Please login to the form below

Not currently logged in

kidney disease

This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

Johnson &Johnson’s SGLT2 inhibitor Invokana worked so well in a trial involving diabetics with chronic kidney disease that the study has been halted early – potentially opening up a lucrative new ... Nearly half of all people with type 2 diabetes

Latest news

More from news
Approximately 20 fully matching, plus 130 partially matching documents found.

Latest Intelligence

  • The invisible army The invisible army

    Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease. ... inflammatory bowel disease and multiple sclerosis.

  • Business as usual Business as usual

    He also cautioned delegates over 'dual use', describing a situation where ferric citrate was promoted at a kidney disease symposium. ... It was described as being FDA-approved - which it is, but not for the treatment of kidney disease.

  • Deal Watch February 2016 Deal Watch February 2016

    The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases. ... licence. 105. †† Genexine/ Shanghai Chemo

  • Deal Watch December 2015 Deal Watch December 2015

    Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 397. Akebia (US). Mitsubishi. Collaboration, licence. Vadadustat for treatment of anaemia in chronic kidney disease.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Making good practice common practice in rare disease

    However, fatigue scores can’ t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....